Cancer Network

01/07/2026

🎙️ This week's episode of Oncology On the Go is here🎙️

Listen as Jose G. Trevino, II, MD, FACS, discusses patient and physician education to help recognize early signs of pancreatic ductal adenocarcinoma.

https://hubs.li/Q03ZLGxt0

Jose G. Trevino, II, MD, FACS, emphasized educating patients and physicians alike to help recognize early signs of pancreatic ductal adenocarcinoma.

01/07/2026

💉 Isatuximab with carfilzomib and dexamethasone conferred efficacy and safety in relapsed/refractory multiple myeloma regardless of subcutaneous administration via on-body injector or manual injection. 💉

Click for more ➡️ https://hubs.li/Q03ZLGkL0

Data from the IZALCO trial support the use of subcutaneous on-body injector administration of an isatuximab-based regimen in relapsed/refractory multiple myeloma.

01/07/2026

Adding tafasitamab and lenalidomide to R-CHOP improved PFS (HR, 0.75; 95% CI, 0.59-0.96; P = .019), and met the secondary end point of EFS based on investigator assessment.

⬇️ Read more here ⬇️
https://hubs.li/Q03ZLrp40

01/07/2026

The FDA has greenlit a new investigational study for (Z)-endoxifen, targeting patients with metastatic ER+/HER2– breast cancer, following pharmacodynamic data from the phase 2 EVANGELINE trial.

Expert Takeaways:
✅ High Response Rates: 86% of patients in the run-in achieved a Ki-67 of ≤10% within one month.
✅ Overcoming Resistance: Unlike legacy SERMs, (Z)-endoxifen targets PKCβ1, offering a potential solution for tumors resistant to aromatase inhibitors and fulvestrant.
✅ Precision Dosing: The 40 mg daily dose showed consistent systemic exposure regardless of CYP2D6 metabolism.

Learn more here: https://hubs.li/Q03ZLcBN0

Previously, the phase 2 EVANGELINE trial assessed treatment with (Z)-endoxifen in this patient group.

01/06/2026

An investigational NDA for ALA-101, an allogeneic CAR invariant NK T-cell therapy platform, has been submitted to the FDA for CD19+ non-Hodgkin lymphoma and leukemia.

⬇️ Read the full article here ⬇️
https://hubs.li/Q03ZyMbT0

An investigational new drug application for ALA-101 has been submitted to the FDA for the treatment of CD19-positive non-Hodgkin lymphoma and leukemia.

01/06/2026

There's no cure for lymphedema. That's precisely why it's so important to experts do all they can to prevent its progression.

⬇️ Read here to learn about another way to identify lymphedema early ⬇️
https://hubs.li/Q03Zz1Lg0

| VCU Massey Comprehensive Cancer Center

01/06/2026

BI-1808, an anti-TNFR2 antibody, plus pembrolizumab was safe and well-tolerated among patients with recurrent ovarian cancer.

Read more here: https://hubs.li/Q03ZyH6P0

01/06/2026

After positive results from the Phase 2 SUMMIT trial were presented at , an NDA has been submitted to the FDA for bezuclastinib in nonadvanced systemic mastocytosis.

The agent has high potency and specificity:
✅ Significant reduction in mast cell aggregates (from 74% to 13% by week 24).
✅ 91% overall response rate in exploratory pathologic response assessments.
✅ Pronounced reduction in mast cells expressing CD25 or CD30 compared to placebo.

Explore the clinical data on CancerNetwork: https://hubs.li/Q03Zyr9j0

Preclinical data from the phase 2 SUMMIT trial presented at the 2025 ASH meeting support the submission for bezuclastinib in this patient group.

01/05/2026

Receipt of early interactive human coaching via a mobile app yields fewer symptoms in HRQOL scales compared with conventional counseling in patients with gastric cancer postgastrectomy.

Read more here: https://hubs.li/Q03ZnWXR0

Although findings did not show differences in eating restrictions 1 month following gastrectomy, the mobile intervention may help with symptom management.

01/05/2026

Bioimpedance spectroscopy is another non-invasive method to identify patients with early-stage lymphedema.

Check out more of Paschalia Mountziaris, MD, PhD's, thoughts here: https://hubs.li/Q03ZnXd60

| VCU Massey Comprehensive Cancer Center

01/05/2026

The FDA's approval for narsoplimab comes after the agent yielded a CR rate of 61% and 68% in 2 separate studies. Narsoplimab also led to a 3- to 4-fold lower risk of mortality.

https://hubs.li/Q03ZnWjz0

01/05/2026

Adding nivolumab and ipilimumab to lutetium-177-PSMA improved efficacy outcomes vs the radioligand alone in patients with advanced castration-resistant prostate cancer.

Read more here: https://hubs.li/Q03ZnWdr0

A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.